Comparison of the Efficacy and Safety between Adjuvant and Palliative Anti-PD-1 Treatment of Stage 4 Oligometastatic Melanoma

Comparison of the Efficacy and Safety between Adjuvant and Palliative Anti-PD-1 Treatment of Stage 4 Oligometastatic Melanoma

Authors

  • Marek Pasek Department of Dermatology and Venereology, Third School of Medicine, Charles University
  • Petr Arenberger Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University and Královské Vinohrady University Hospital, Prague, Czech Republic https://orcid.org/0000-0002-4800-5877
  • Vojtech Tretera Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University and Královské Vinohrady University Hospital, Prague, Czech Republic https://orcid.org/0009-0002-5557-6026
  • Martin Palkovsky Department of Oncology, Third Faculty of Medicine, Charles University, Prague, Czech Republic https://orcid.org/0009-0007-9154-188X
  • Jana Vránová Department of Medical Biophysics and Medical Informatics, Third Faculty of Medicine, Charles University and Královské Vinohrady University Hospital, Prague, Czech Republic https://orcid.org/0000-0002-9971-5385
  • Monika Arenbergerova Department of Dermatology and Venereology, Third Faculty of Medicine, Charles University and Královské Vinohrady University Hospital, Prague, Czech Republic https://orcid.org/0000-0002-7919-9619

Keywords:

adjuvant, palliative, immunotherapy, anti-PD-1, oligometastatic, melanoma

References

Larkin J, Del Vecchio M, Mandalá M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. Clin Cancer Res. 2023; 29(17):3352-3361. DOI: 10.1158/1078-0432.CCR-22-3145. PMID: 37058595.

Livingstone E, Zimmer L, Hassel JC, et al. Dermatologic Cooperative Oncology Group. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet. 2022;400(10358):1117-1129. DOI: 10.1016/S0140-6736(22)01654-3. PMID: 36099927.

Amaral T, Ottaviano M, Arance A, et al. ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(1):10-30. DOI: 10.1016/j.annonc.2024.11.006. PMID: 39550033.

Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023;388(9):813-823. DOI: 10.1056/NEJMoa2211437. PMID: 36856617.

Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. N Engl J Med. 2024; 391(18):1696-1708. DOI: 10.1056/NEJMoa2402604. PMID: 38828984.

Downloads

Published

2026-01-30

Issue

Vol. 16 No. 1 (2026): 2026 Vol 16, No 1 | January

Section

Research Letter

License

Copyright (c) 2026 Marek Pasek, Petr Arenberger, Vojtech Tretera, Martin Palkovsky, Jana Vránová, Monika Arenbergerova

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

How to Cite

1.
Pasek M, Arenberger P, Tretera V, Palkovsky M, Vránová J, Arenbergerova M. Comparison of the Efficacy and Safety between Adjuvant and Palliative Anti-PD-1 Treatment of Stage 4 Oligometastatic Melanoma. Dermatol Pract Concept. 2026;16(1):6483. doi:10.5826/dpc.1601a6483

Share

Crossref
Scopus
Google Scholar
Europe PMC